STRO-006 / Sutro Biopharma - LARVOL DELTA

STRO-006: An Integrin beta-6-targeting ADC demonstrates favorable safety profile and potent antitumor activity in preclinical solid tumors (AACR 2026) - "These results suggest that STRO-006 is a promising candidate for the treatment of multiple carcinomas and supports further clinical investigation. A Phase 1, first-in-human study is planned to assess the safety and activity of STRO-006."

ADC • First-in-human • Preclinical • Esophageal Cancer • Gastric Cancer • Head and Neck Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Pancreatic Cancer • Solid Tumor • Squamous Cell Carcinoma of Head and Neck • ITGB6

A highly selective integrin β6 (ITGB6) ADC, STRO-006 is expected to enter clinical development in 2026 for the treatment of multiple solid tumors (GlobeNewswire)

New trial • Solid Tumor

Sutro Biopharma Reports First Quarter 2025 Financial Results and Business Highlights (GlobeNewswire) - "Corporate and Program Updates:...STRO-006: Sutro’s differentiated integrin beta-6 (ITGB6) ADC is expected to enter clinical development in 2026, aimed at multiple solid tumors....21st Annual PEGS Boston: The Essential Proteins Engineering & Cell Therapy Summit: In May, Sutro will present promising preclinical data with STRO-006, highlighting its superior anti-tumor activity compared to first generation ITGB6 ADCs at clinically relevant dose levels, as well as its favorable PK and tolerability profile."

New trial • Preclinical • Solid Tumor

Sutro Biopharma Announces Strategic Portfolio Review Resulting in the Prioritization of its Next-Generation ADC Pipeline (GlobeNewswire) - "STRO-006: Sutro’s differentiated integrin beta-6 ADC is expected to enter clinical development in 2026 aimed at multiple solid tumors."

IND • Solid Tumor